Peter Rothwell (University of Oxford, Oxford, UK) and colleagues report in The Lancet that long-term use of aspirin in people aged 75 or older is associated with a higher than expected risk of disabling or fatal bleeding. They add that, to counter this risk, patients over 75 who take aspirin on a daily basis should be prescribed a proton-pump inhibitor to reduce the risk of bleeding.
A pooled patient-level analysis of patients undergoing physiological assessment, with either fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR), indicates that deferring coronary interventions in contemporary clinical practice is safe—particularly in stable patients. However, a small but significantly higher risk of major adverse cardiac events (MACE) at one year was found when revascularisation deferral was performed in patients with acute coronary syndrome.
Sameer Arora (Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, USA) and others report in Catheterizations and Cardiovascular Interventions that early percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) significantly increases 28-day survival. They add that this finding is independent of factors such as demographics and comorbidities.
Edwards Lifesciences has received US Food and Drug Administration (FDA) approval for aortic and mitral valve-in-valve procedures using the Edwards Sapien 3 transcatheter heart valve. According to a company release, the Sapien 3 valve is the first transcatheter heart valve approved in the USA for the treatment of both aortic and mitral patients who are at high risk for a subsequent open-heart surgery to replace their bioprosthetic valve.
Claret Medical has received regulatory clearance from the FDA for its Sentinel cerebral protection system, via de novo classification, meaning that the device can now be marketed in the USA. It also means that Sentinel is the first such device to become available in the USA. Sentinel is designed to be used during transcatheter aortic valve implantation (TAVI) procedures to reduce the risk of stroke by capturing and removing debris dislodged by such procedures before it reaches the brain.
The first ever Inspiris Resilia aortic valve (Edwards Lifesciences) implantation procedures have successfully taken place in two UK hospitals—King’s College and Royal Brompton and Harefield NHS Trust (both London, UK).
Micell Technologies has announced positive twelve-month data from its DESSOLVE III clinical trial comparing the company’s MiStent with Abbott’s Xience. The study met its primary endpoint, showing non-inferior safety and effectiveness outcomes in a complex patient population for the MiStent sirolimus-eluting absorbable polymer coronary stent system vs. the Xience everolimus-eluting coronary stent system. Robbert J de Winter, Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands, presented the data at EuroPCR 2017.
Singulex has been granted CE mark for its ultra-sensitive troponin assay (cTnl), the first offered by the company’s Sgx Clarity system, a fully-automated, in vitro diagnostics platform powered by Single Molecule Counting technology.
Boston Scientific Corporation has announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on transcatheter aortic valve implantation (TAVI) devices. With the completion of the acquisition, Boston Scientific immediately began selling Symetis’s Acurate TA and Acurate neo/TF systems in Europe and in other geographies outside of the USA. Therefore, Symetis is now part of the Boston Scientific Interventional Cardiology division
David Wald (Barts Heart Centre, St Bartholomew’s Hospital, London, UK) and his 16-year-old son Ben have designed a system that will enable surgeons, via a coded message, to leave details about a patient’s procedure inside the patient themselves to provide details about the procedure to any surgeons performing later interventions.
The US Food and Drug Administration (FDA) has cleared Stroke2prevent’s A-view device for commercialisation on the US market. The A-view is a balloon catheter designed for visualisation of the aortic arch by transoesophageal echocardiography (TEE).
Statins are associated with improved heart structure and function, according to research presented at the annual Cardiovascular Magnetic Resonance conference of the European Association of Cardiovascular Imaging (EACVI) (EuroCMR; 25–27 May, Prague, Czech Republic). The benefits were above and beyond the cholesterol lowering effect of statins.
Quitting methamphetamine use can reverse the damage the drug causes to the heart and improve heart function in abusers when combined with appropriate medical treatment, potentially preventing future drug-related cases of heart failure or other worse outcomes, according to a study published in JACC: Heart Failure.
Diesel pollution is linked with heart damage, according to research presented at the annual Cardiovascular Magnetic Resonance conference of the European Association of Cardiovascular Imaging (EACVI) (EuroCMR; 25–27 May, Prague, Czech Republic).
BioVentrix has announced the first clinical use of its closed-chest Revivent TC transcatheter ventricular enhancement system at the Deutsches Herzzentrum Berlin in Berlin, Germany. The less invasive ventricular enhancement (LIVE) procedure was performed by interventional cardiologist Christoph Klein and cardiothoracic surgeon Felix Hennig, with contributions from Sebastian Kelle, chief of cardiovascular imaging at the centre.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos